In a victory for Teva Pharmaceutical Industries, the U.S. Supreme Court today refused to revive Helsinn Healthcare S.A.’s patent on an anti-nausea drug Aloxi.

The decision was unanimously upheld in a lower court ruling which canceled Helsinn’s patent on the drug for violating a provision in U.S. patent law that forbids sales of an invention before applying for a patent.

Teva launched its generic version of the drug in March 2018 after the lower court invalidated the patent.

Subscribe To Our Newsletter

Would you like to receive our popular weekly news alerts straight to your inbox? Solely patent focused and only sent once a week means you can guarantee there will be something you are interested in reading instead of clogging up your inbox with junk. Sign up now!

You have Successfully Subscribed!